Revamped EU drug regulations increase accessibility but limit innovation?
The European Union’s pharmaceutical industry could face a serious change in operations after Brussels published a proposal for the revamping of certain laws governing the industry.
As one of the biggest modernisation of these laws in 20 years, the market will see a shift in access across European countries to new treatments and generic drugs. The changes should serve to reduce the difference in accessibility to certain medications, and the difference in prices that can be seen in drugs.
One of these amendments includes reducing the length of time a drugmaker can claim exclusivity over a generic from 10 years to eight. However, companies can still earn two further years of protection by launching any new medicine in all 27 member states within the first two years.
EU Health Commissioner Stella Kyriakides stated that the new system "would provide access to new medicines to around 70 million more citizens compared to today".
The EU Health Commission states the overhaul will create a single market for medicines in Europe, shifting the focus on to better provision of healthcare rather than playing to the pharmaceutical industry with overly generous incentives.
Pharmaceutical companies have voiced concerns over the reforms, convinced that it will curb innovation by removing the competitive edge, rather than increase it.
CEO of Novo Nordisk, Lars Fruergaard Jørgensen stated on Wednesday that "the proposals are poison for innovation and competitiveness in Europe."
GSK affirmed that the EU must "regulate for growth and competitiveness" because companies "have choices on where our capital and resources are focused".
The aim of the alterations is mostly to ensure that drug shortages, such as we’ve seen in the last few months, will not occur again, with a failsafe meaning that companies will have to disclose any issues with the supply chain earlier on so that contingencies can be made. The regulations also hope to make the regulators int eh Eu more efficient and improve the speed at which new drugs can be approved for market.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance